At the same time, PALTAN (NCT02907918) trial is evaluating the pCR rate of newly diagnosed clinical stage II or III HR+/HER2+ breast cancer patients by the use of Palbociclib in combination with neoadjuvant letrozole and weekly trastuzumab. Here, ERBB2 is linked to breast carcinoma.